论文部分内容阅读
目的:探讨99Tcm-MIBIS PECT/CT异机融合断层显像对肺癌的临床诊断价值。方法:选择65例肺部占位性病变患者行99Tcm-MIBI SPECT/CT异机融合断层显像,分析显像结果,计算SPECT/CT断层融合显像的摄取比值(UR);依据病理诊断将患者分成肺癌组和良性病变组,以良性病变组UR的x+1s为诊断阈值,评价其对肺癌的诊断效能。结果:45例肺癌患者SPECT断层融合显像的UR为2.56±0.53;20例肺部良性病灶患者UR为1.47±0.42,差异有统计学意义(P<0.05);99Tcm-MIBI SPECT/CT异机融合断层显像对肺癌诊断的灵敏度、特异度和准确度分别为86.67%、85.00%、86.15%;假阳性率和假阴性率分别为15.00%和13.33%;阳性预测值和阴性预测值分别为92.86%和73.91%。结论:99Tcm-MIBI SPECT/CT异机融合断层显像对肺癌诊断有较高的临床价值,为制定治疗方案提供重要依据。
Objective: To investigate the clinical value of 99Tcm-MIBIS PECT / CT in the diagnosis of lung cancer. Methods: Sixty-nine patients with lung space-occupying lesions underwent 99Tcm-MIBI SPECT / CT fusion tomography. The imaging results were analyzed and the ratio of SPECT / CT fusion imaging was calculated. According to the pathological diagnosis, Patients were divided into lung cancer group and benign lesion group, and the benign lesion group UR x + 1s as the diagnostic threshold to evaluate the diagnostic efficacy of lung cancer. Results: The UR of SPECT fusion imaging in 45 lung cancer patients was 2.56 ± 0.53. UR in the 20 patients with benign lung lesions was 1.47 ± 0.42 (P <0.05). The 99Tcm-MIBI SPECT / CT allograft The sensitivity, specificity and accuracy of fusion tomography for the diagnosis of lung cancer were 86.67%, 85.00% and 86.15% respectively; the false-positive rate and false-negative rate were 15.00% and 13.33% respectively; the positive predictive value and negative predictive value were 92.86% and 73.91%. Conclusion: 99Tcm-MIBI SPECT / CT fusion imaging has high clinical value in the diagnosis of lung cancer, and provides an important basis for the development of the treatment plan.